Introduction
In the past two decades azolotetrazinones have been the focus of medicinal chemists because of the outstanding antineoplastic activity shown by two imidazotetrazine derivatives temozolomide, and mitozolomide. The lead compound, mitozolomide, has demonstrated antitumor activity in patients with small cell carcinoma of the lung and malignant melanoma; however, severe and unpredictable myelosuppression effects precluded its further development. Temozolomide (TMZ), a 3-methyl analog of mitozolomide, is currently on the market with the trade name Temodal® and is used against malignant melanoma, mycosis fungoides, and brain tumors. [4] [5] [6] TMZ is a prodrug that undergoes spontaneous degradation at physiologic pH to form the 5-(3-methyl-1-triazeno)-imidazole-4-carboxamide (MTIC), which subsequently fragments into 5-aminoimidazole-4-carboxamide (AIC) and the DNA-methylating agent, methyldiazonium. This latter likely undergoes an S N 2 alkylation at the N-7 and/or O-6 sites of a guanine residue (Scheme 1). 7, 8 Scheme 1. Temozolomide mechanism of activation.
More recently temozolomide and its esters are primarily indicated for the treatment of malignant glioma. [9] [10] [11] We have previously reported on the synthesis and the antitumor activity of pyrrolo [2,1-d] [1, 2, 3, 5] tetrazine-4(3H)-ones (1) which exhibited a significant growth inhibition efficacy in many cancer cell lines, with GI 50 values in the low micromolar or sub-micromolar range and reaching, in some cases nanomolar concentrations.
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Figure 2. Pyrrolo-tetrazinones (1) and indolo-tetrazinones (2).
Pyrrolotetrazinones, did not show any selectivity with respect to the CNS cancer and melanoma sub-panels against which temozolomide showed curative properties, however they exhibited excellent responses in the breast cancer and leukaemia sub-panels. 13 Nanostructured lipid carrier (NLC) loaded with pyrrolotetrazinones tested in vitro against hepatocellular carcinoma (HuH-6 and HuH-7) and human prostate cancer (PC-3) cell lines have shown an enhancement of cytotoxicity. 14 SAR studies as well as the computerised analysis COMPARE 15 indicated that pyrrolotetrazinones have a mode of action different from that of temozolomide. Studies directed to elucidate the biochemical mechanism of action of this class of compounds indicated that they interfere with the microtubule network, block mitosis and that mitochondria and caspases play a central role in the activation of the executioner phase of pyrrolotetrazinonesinduced apoptosis. 16 Benzocondensation of the pyrrolotetrazinone ring led to [1, 2, 3, 5] tetrazino [5,4-a] indole-4-one (2) derivatives which showed antiproliferative activity in the micromolar range. These latter, at variance with pyrrolotetrazinones, exhibited good selectivity with respect to the CNS sub-panel in which the lead compound, as already stated, showed curative properties. 17 Encouraged by these results we thought it was interesting to verify whether the condensation of the pyrrolotetrazine system with a pyrido moiety increases the antineoplastic activity.
In this paper we focus our attention on the synthesis of the new ring system pyrido 
Results and Discussion
The synthesis of pyridopyrrolo [1, 2, 3, 5] tetrazines 9a-l was accomplished by the route depicted in Scheme 2.
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a For designation of R in 8a-l and 9a-l, see Table 1 .
Scheme 2 a
Reaction between the 2-chloro-3-nitropyridine 3 and the potassium enolate of ethyl cyanoacetate 4 gave derivative 5 in high yield (92%). Reduction of this latter with iron and acetic acid at room temperature yielded the 2-amino-3-ethoxycarbonyl-pyrrolo[3,2-b]pyridine 6 (yield 80%). The 2-diazo-3-ethoxycarbonyl-pyrrolo[3,2-b]pyridine 7 was obtained, in excellent yield (96%), by diazotization of the corresponding amine 6. The reaction was carried out in 80% acetic acid with stoichiometric amount of sodium nitrite under nitrogen atmosphere in the dark followed by neutralization with sodium carbonate. The strict control of the temperature at 0°C both during diazotization and neutralization is crucial in obtaining a good yield. The structure of 2-diazo-pyrrolo[3,2-b]pyridine 7 was confirmed by analytical and spectral data (IR, 1 H and 13 C NMR). In particular the IR spectra showed a sharp and strong band at 2198 cm -1 .
The pyridopyrrolo-tetrazines 9a-l have been prepared in moderate to good yields (35-80%) by reaction of the diazo 7 with stoichiometric amounts of proper isocyanates 8a-l in DCM at room temperature for 12-48 h. The same reactions carried out under microwave irradiation, with a CEM discover apparatus, gave the pyridopyrrolo-tetrazines 9a-l with higher yield (62-95%) in a shorter time (3 min) ( Table 1 ). The structure of all derivatives 9 was confirmed by spectroscopic data. Biological screenings were performed, on nine selected pyridopyrrolotetrazines (9a, 9b 9c, 9d, 9e, 9f, 9g, 9k, 9i), by the National Cancer Institute (Bethesda, MD), at one dose concentration (10 -5 M), for the in vitro disease-oriented antitumor screenings against a panel of about 60 human tumor cell lines that have grouped in disease sub-panel including leukaemia, non-small lung, colon, central nervous system, melanoma, ovarian, renal, prostate, and breast tumors cell lines. 18 The results obtained take into consideration the growth inhibitory power (GI 50 ). None of the tested compounds showed significant activity.
Conclusions
In conclusion the annellation of the pyrido moiety to the pyrrolotetrazine system, also regarded as the aza-substitution in position 4 of the [ . To a solution of 2-amino-3-ethoxycarbonyl-pyrrolo[3,2-b]pyridine 6 (0.62 g, 3 mmol) in glacial acetic acid (6 ml) a solution of sodium nitrite (3 mmol) in a small amount of water (1 ml) was added dropwise at 0°C under a nitrogen atmosphere. The mixture was neutralized at 0°C with saturated Na 2 CO 3 and the yellow solid precipitated was filtered off and dried under vacuum and in the dark. The crude product, quickly shaken in cyclohexane and filtered off, gave 2-diazo-pyrrolo-pyridine 7 (0.62 g): brown powder, m. 
Conventional method (CM)
To a solution of 7 (0.86 g, 2 mmol) in anhydrous DCM (10 ml), the suitable isocyanate 8a-l (2 mmol) in anhydrous DCM (10 ml) was added dropwise at room temperature in the dark under a nitrogen atmosphere. The reaction mixture was stirred for 12-48 h, then the solvent was evaporated under reduced pressure and the residue purified by chromatography with DCM as eluent to give 9a-l (yields 35-80%).
B.
Microwave method (MM) A mixture of 7 (0.43 g, 1 mmol), the suitable isocyanate 8a-l (1 mmol), and anhydrous DCM (5 ml) was irradiated at power of 150 W, temperature of 50°C for 3 min. The solvent was evaporated under reduced pressure and the residue purified by chromatography with DCM as eluent to give 9a-l (yields 62-95%). 
